- Home
- FTHM vs AYTU Comparison
FTHM vs AYTU Comparison
Compare FTHM & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | AYTU |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 27.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FTHM | AYTU |
|---|---|---|
| Price | $0.72 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 134.4K | 31.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,477,000.00 | $27,632,080.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.45 | ★ 277.47 |
| 52 Week Low | $0.40 | $1.65 |
| 52 Week High | $3.37 | $3.07 |
Technical Indicators
Market Signals| Indicator | FTHM | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 56.52 |
| Support Level | $0.70 | $2.13 |
| Resistance Level | $0.92 | $2.46 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.67 | 60.71 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.